

Appendix

Estimated proportion of GC, CT, and TV infections in clinical trial sample was derived from Centers for Disease Control and prevalence 2013 surveillance data and our primary data.

	<u>Chlamydia rate/100,000</u>	<u>Gonorrhea rate/100,000</u>
Maryland	455.3	97.6
Texas	494.8	126.5
California	444.9	89.1
Average	465	104.4

$$\text{CT/GC: } 465/104.4=4.45$$

Demonstration Study: 6 CT infections and 2 TV infections

$$\text{GC}=\text{CT}/4.45=6/4.45=1.35$$

Estimated proportion of GC, CT, and TV in clinical trial:

$$1.35\text{GC} + 2\text{TV} + 6\text{CT} = 9.35$$

$$= 14.4\%\text{GC} + 21.4\%\text{TV} + 64.1\%\text{CT}$$

Estimated proportion choosing eRx vs Clinic Treatment in clinical trial sample was derived from primary data and restriction that GC can only be treated in clinic.

Demonstration Study: 75% chose eRx

Clinical Trial Estimate:

75% of 21.4%TV = 16%

75% of 64.2%CT = 48.2%

0% of 14.4% GC = 0%

Clinical Trial eRx: 64.2%

Demonstration Study: 25% chose clinic treatment

Clinical Trial Estimate:

25% of 21.4%TV = 5.4%

25% of 64.2%CT = 16%

100% of 14.4%GC = 14.4%

Clinical Trial Clinic Treatment: 35.8%

Clinical Trial eRx medication cost:

25%TV (\$1.36) + 75%CT (\$4.63) = \$3.81

Clinical Trial Clinic medication cost:

15%TV (\$1.36) + 45%CT (\$4.63) + 40%GC (\$6.71) = \$4.97